Flo Health’s journey to becoming Europe’s first femtech unicorn, valued at $1 billion, isn’t just a business success story – it’s a masterclass in building trust through unwavering commitments to user privacy and scientific rigor. In an industry often plagued by data scandals and unverified health claims, Flo’s approach offers a blueprint for sustainable growth.

In July 2024, Flo raised more than $200 million in a Series C round led by General Atlantic, achieving a pre-money valuation of $1 billion. This made it the first purely digital consumer women’s health app to reach unicorn status and Europe’s first femtech unicorn, with gross bookings expected to exceed $200 million in 2024 – a 50% year-over-year increase.

Central to this success is an ironclad privacy promise: Flo has “never — and will never — sell your personal data.” The company is the first and only period tracker to achieve dual certification in both ISO 27001 (Security) and ISO 27701 (Privacy), international standards that required nine months of preparation and rigorous external audits.

The trust extends beyond privacy to scientific credibility. Every feature and piece of content is backed by a team of over 140 doctors and health experts. Each article undergoes review by two experts in the field, with references to peer-reviewed articles, medical guidelines, and links to recognized health organizations. The company has published multiple randomized controlled trials proving the app’s effectiveness.

Flo’s Anonymous Mode, recognized as one of TIME’s Best Inventions 2023, exemplifies this trust-first approach. Launched in response to the overturning of Roe v. Wade, it enables users to separate their health information from their identity completely. Rather than keeping this innovation proprietary, Flo open-sourced the technology to benefit the entire femtech ecosystem after settling a class action lawsuit.

The trust-building extends globally through Flo’s Pass It On Project, which has gifted over 20 million premium subscriptions to women in underserved regions. The initiative aims to provide free access to 1 billion women in need, with nearly 12 million women currently benefiting across 66 countries, including India, Indonesia, and Nigeria.

The business results validate this approach. Revenue grew from $35 million in 2022 to $112 million in 2023, while losses fell from $35 million to $25 million over the same period. The company’s nearly 500 employees globally are expanding research and development, with plans to increase headcount in top-tier talent.

In a femtech market projected to reach $60 billion by 2027, Flo’s success stands out. While the sector has historically been underfunded – European femtech raised just $191 million in 2023 compared to $9.7 billion for broader healthtech – Flo’s approach has attracted major investors. As of 2024, only eight femtech companies globally have achieved billion-dollar valuations: seven in North America and Flo in Europe, even as legal challenges in the industry highlighted the importance of privacy practices and while competitors faced jury verdicts for data violations.

General Atlantic Principal Jessie Cai explained the investment rationale: “We have been lucky enough to watch the Flo team over the past five years build a beloved, mission-critical app for women globally. We believe Flo is a category leader and look forward to leveraging our deep expertise across disruptive consumer technology and subscription platforms.”

The trust manifests in user testimonials and professional endorsements. As the #1 OB-GYN recommended app for female health, trusted by over 380 million users worldwide, Flo has achieved what many digital health companies struggle with: credibility among both healthcare professionals and consumers. One OB-GYN noted: “I know that I can trust the peer-approved articles that are available through Flo.”

By proving that ethical practices and business success aren’t mutually exclusive, Flo Health has redefined what it means to be a femtech leader. In an industry where trust is currency, their formula is simple yet revolutionary: protect user data fiercely, verify every health claim scientifically, and share innovations that advance women’s health globally. The billion-dollar valuation isn’t just a financial milestone – it’s the market’s validation that genuine trust is the most valuable asset of all.